(Q53264472)

12 May 2018

review article

1 reference

title

Advances in the preclinical testing of cancer therapeutic hypotheses. (English)

1 reference

12 May 2018

1 reference

Giordano Caponigro

1

1 reference

12 May 2018

William R Sellers

series ordinal

2

1 reference

12 May 2018

publication date

1 March 2011

1 reference

12 May 2018

Nature Reviews Drug Discovery

published in

1 reference

12 May 2018

volume

10

1 reference

12 May 2018

issue

3

1 reference

12 May 2018

page(s)

179-187

1 reference

12 May 2018

https://scigraph.springernature.com/pub.10.1038/nrd3385

exact match

0 references

cites work

International network of cancer genome projects

1 reference

1-amino-4-benzylphthalazines as orally bioavailable smoothened antagonists with antitumor activity

21 January 2018

1 reference

GDC-0449-a potent inhibitor of the hedgehog pathway

21 January 2018

1 reference

Pharmacology of novel steroidal inhibitors of cytochrome P450(17) alpha (17 alpha-hydroxylase/C17-20 lyase).

21 January 2018

1 reference

Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor

21 January 2018

1 reference

Arimidex: a potent and selective fourth-generation aromatase inhibitor

21 January 2018

1 reference

Shh pathway activity is down-regulated in cultured medulloblastoma cells: implications for preclinical studies

21 January 2018

1 reference

Efficient tumour formation by single human melanoma cells

21 January 2018

1 reference

Timeline: Chemotherapy and the war on cancer.

21 January 2018

1 reference

A history of cancer chemotherapy

21 January 2018

1 reference

The Biological Actions and Therapeutic Applications of the B-Chloroethyl Amines and Sulfides

21 January 2018

1 reference

Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders

21 January 2018

1 reference

Fluorinated pyrimidines, a new class of tumour-inhibitory compounds

21 January 2018

1 reference

The NCI60 human tumour cell line anticancer drug screen

21 January 2018

1 reference

Analysis of Food and Drug Administration-approved anticancer agents in the NCI60 panel of human tumor cell lines

21 January 2018

1 reference

Integrating data on DNA copy number with gene expression levels and drug sensitivities in the NCI-60 cell line panel

21 January 2018

1 reference

Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma

21 January 2018

1 reference

Predicting cancer drug response by protoeomic profiling

21 January 2018

1 reference

Gene expression patterns within cell lines are predictive of chemosensitivity

21 January 2018

1 reference

Systematic variation in gene expression patterns in human cancer cell lines

21 January 2018

1 reference

A gene expression database for the molecular pharmacology of cancer

21 January 2018

1 reference

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

An information-intensive approach to the molecular pharmacology of cancer.

21 January 2018

1 reference

Dual inhibition of topoisomerase II and tubulin polymerization by azatoxin, a novel cytotoxic agent.

21 January 2018

1 reference

Development of the proteasome inhibitor PS-341.

21 January 2018

1 reference

Characterizing the cancer genome in lung adenocarcinoma

21 January 2018

1 reference

Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis

21 January 2018

1 reference

Somatic mutations affect key pathways in lung adenocarcinoma

21 January 2018

1 reference

Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population

21 January 2018

1 reference

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

21 January 2018

1 reference

Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors

21 January 2018

1 reference

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

21 January 2018

1 reference

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer

21 January 2018

1 reference

Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK

21 January 2018

1 reference

EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer

21 January 2018

1 reference

A mouse model for EML4-ALK-positive lung cancer

21 January 2018

1 reference

Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244)

21 January 2018

1 reference

Molecular target class is predictive of in vitro response profile

21 January 2018

1 reference

Modeling genomic diversity and tumor dependency in malignant melanoma

21 January 2018

1 reference

Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions

21 January 2018

1 reference

AZD6244 (ARRY-142886), a potent inhibitor of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase 1/2 kinases: mechanism of action in vivo, pharmacokinetic/pharmacodynamic relationship, and potential for combination in precl

21 January 2018

1 reference

KRAS/BRAF mutation status and ERK1/2 activation as biomarkers for MEK1/2 inhibitor therapy in colorectal cancer

21 January 2018

1 reference

Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers

21 January 2018

1 reference

PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers

21 January 2018

1 reference

Systematic discovery of multicomponent therapeutics

21 January 2018

1 reference

Identifying genotype-dependent efficacy of single and combined PI3K- and MAPK-pathway inhibition in cancer

21 January 2018

1 reference

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

21 January 2018

1 reference

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC.

21 January 2018

1 reference

Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma

21 January 2018

1 reference

Genomic changes and gene expression profiles reveal that established glioma cell lines are poorly representative of primary human gliomas

21 January 2018

1 reference

Human glioblastoma-derived cancer stem cells: establishment of invasive glioma models and treatment with oncolytic herpes simplex virus vectors

21 January 2018

1 reference

Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice

21 January 2018

1 reference

Tumorigenicity of the met proto-oncogene and the gene for hepatocyte growth factor

21 January 2018

1 reference

Hedgehog signaling is restricted to the stromal compartment during pancreatic carcinogenesis

21 January 2018

1 reference

A paracrine requirement for hedgehog signalling in cancer

21 January 2018

1 reference

The mighty mouse: genetically engineered mouse models in cancer drug development

21 January 2018

1 reference

Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer

21 January 2018

1 reference

Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma

21 January 2018

1 reference

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

From basic research to clinical development of MEK1/2 inhibitors for cancer therapy

21 January 2018

1 reference

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

Phase II multicenter study of abiraterone acetate plus prednisone therapy in patients with docetaxel-treated castration-resistant prostate cancer

21 January 2018

1 reference

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

21 January 2018

1 reference

Phase I clinical trial of the CYP17 inhibitor abiraterone acetate demonstrating clinical activity in patients with castration-resistant prostate cancer who received prior ketoconazole therapy.

21 January 2018

1 reference

PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications

21 January 2018

1 reference

ONCOGENESIS: Landscaping the Cancer Terrain

21 January 2018

1 reference

Tumor growth need not be driven by rare cancer stem cells

21 January 2018

2 references

31 March 2020

12 December 2020

Topoisomerase II inhibition and cytotoxicity of the anthrapyrazoles DuP 937 and DuP 941 (Losoxantrone) in the National Cancer Institute preclinical antitumor drug discovery screen

1 reference

Chimeric mouse tumor models reveal differences in pathway activation between ERBB family- and KRAS-dependent lung adenocarcinomas

31 March 2020

1 reference

Cancer research. Looking for a target on every tumor

31 March 2020

1 reference

Landscaping the cancer terrain

31 March 2020

1 reference

12 December 2020

CWR22: androgen-dependent xenograft model derived from a primary human prostatic carcinoma

1 reference

12 December 2020

Establishment and characterization of a new human prostatic cancer cell line: DuCaP.

1 reference

12 December 2020

Actinomycin D in childhood cancer; a preliminary report

1 reference

12 December 2020

Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.

1 reference

12 December 2020

Characterization of a novel androgen-sensitive, prostate-specific antigen-producing prostatic carcinoma xenograft: LuCaP 23.

1 reference

12 December 2020

Studies in 2-acetylaminofluorene carcinogenesis. III. The utilization of uracil-2-C14 by preneoplastic rat liver and rat hepatoma.

1 reference

12 December 2020

VCaP, a cell-based model system of human prostate cancer

1 reference

12 December 2020

THE VINCA ALKALOIDS: A NEW CLASS OF ONCOLYTIC AGENTS.

1 reference

12 December 2020

Halichondrin B and homohalichondrin B, marine natural products binding in the vinca domain of tubulin. Discovery of tubulin-based mechanism of action by analysis of differential cytotoxicity data

1 reference

12 December 2020

The effect of actinomycin D on experimental ascitic tumors in the mouse

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRD3385

1 reference

12 May 2018

1 reference

12 May 2018